Bolt Biotherapeutics (NYSE: BOLT) — Perfil da empresa, notícias e dados financeiros
Bolt Biotherapeutics specializes in immuno-oncology platforms, developing innovative cancer treatments using immune-stimulating antibody conjugates.
Bolt Biotherapeutics
Bolt Biotherapeutics (NASDAQ:BOLT) is a biotechnology company dedicated to revolutionizing cancer treatment through the development of its innovative immuno-oncology platforms. The company's flagship projects focus on harnessing the body's immune system to target and destroy cancer cells, leveraging its cutting-edge research in the field of Immune-Stimulating Antibody Conjugates (ISACs). Bolt Biotherapeutics aims to pioneer treatments that offer improved outcomes for patients with various types of cancer. With a commitment to innovation and patient care, Bolt Biotherapeutics is actively advancing its pipeline of potential cancer therapies, driven by a deep understanding of the complex interactions within the tumor microenvironment.
Resumo
Operações
Produtos e/ou serviços de Bolt Biotherapeutics
- A pioneering project focusing on immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively.
- Development of a next-generation bolt-on technology designed to enhance the efficacy of existing cancer therapies.
- Creation of a unique platform for targeted drug delivery, especially for hard-to-reach tumors, improving treatment accuracy and reducing side effects.
- Advancement in personalized cancer vaccine technology, tailoring treatments to individual patient's tumor markers for increased effectiveness.
- Exploration of antibody-drug conjugates (ADC) utilizing cutting-edge linker technology for improved stability and tumor targeting.
- Research into modulating the tumor microenvironment to support immune system access and activity against cancer cells.
equipe executiva do Bolt Biotherapeutics
- William P. QuinnCEO, CFO, President, Secretary & Director
- Grant YonehiroCOO & Chief Business Officer
- Sarah NemecSenior VP of Finance & Principal Accounting Officer
- Michael N. AlonsoSenior Vice President of Research
- Justin KenkelSenior Principal Scientist
Principais indicadores financeiros
Resultados divulgados pela Bolt Biotherapeutics, em USD.
- Cap. de mercado
- 15,5 mi
- Receita (TTM)
- 4,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -16.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,7 mi | -34,6 mi | -33,4 mi | |
| 7,7 mi | -73 mi | -63,1 mi | |
| 7,9 mi | -76,2 mi | -69,2 mi | |
| 5,7 mi | -90,3 mi | -88,1 mi |